Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate Primary Liver Cancer at the 3rd Asian Conference on Tumor ...
LAWRENCEVILLE, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the presentation of data from the Company’s HEAT Study, highlighting the curative potential for ThermoDox® plus …